Clinical Trials Logo

Clinical Trial Summary

This is a phase III , randomized, double-blinded, multicenter clinical study to compare efficacy and safety of AK105 (Anti-PD1 antibody) combined with Carboplatin and Pemetrexed vs Placebo combined with Carboplatin and Pemetrexed as first-line therapy in patients with EGFR and ALK wild type metastatic nonsquamous non-small cell lung cancer.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03866980
Study type Interventional
Source Akeso
Contact
Status Terminated
Phase Phase 3
Start date November 27, 2018
Completion date December 31, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT03692442 - Evaluation of Efficacy and Toxicity of Nivolumab Monotherapy for Advanced Non-small Cell Lung Cancer After First-line Treatment Failure Based on Second-generation Sequencing and Liquid Chip Platform
Recruiting NCT03769103 - Study of Osimertinib + SRS vs Osimertinib Alone for Brain Metastases in EGFR Positive Patients With NSCLC Phase 2
Not yet recruiting NCT06463171 - Phase II Trial of Almonertinib Plus Lastet for EGFR+ Non-small Cell Lung Cancer Phase 2
Terminated NCT02129699 - Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapy Phase 3
Recruiting NCT05127382 - Osimertinib as 1st Line Therapy for Patients With Advanced EGFR Positive Non-Small Cell Lung Cancer
Completed NCT03866993 - A Study of Anti-PD-1 AK105 in Patients With Metastatic Squamous Non-small Cell Lung Cancer Phase 3
Not yet recruiting NCT04184921 - Combination of Osimertinib and Aspirin to Treat EGFR Mutation NSCLC Patients